FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2300929849> ?p ?o ?g. }

• W2300929849 abstract "17096 Background: Second-line chemotherapy has become almost routine in non-small cell lung cancer (NSCLC) patients (pts) with good performance status (PS). The availability of the new pharmacological agents opens up new possibilities for their use in pts who have retained a good PS following relapse or progression after first-line chemotherapy. Paclitaxel (PTX) and Gemcitabine (GEM) are among the most active new agents in NSCLC and are worth considering for second-line chemotherapy. In phase II study, we evaluated the tolerability and activity of the combination of weekly PTX and GEM in second-line treatment of NSCLC. Methods: PTX (100mg/m 2 ) and GEM (1000 mg/m 2 ) were administered on days 1 and 8 at every 3–4 weeks. A total of 40 pts (M/F, 27/13 pts; median age 59.3 years [33–75]; PS 0/1/2, 7/27/6 pts) were enrolled between October 2000 and July 2003. Results: The number of cycles conducted was 1 in 5 pts, 2 in 8 pts, 3 in 10 pts, and 4 in 17 pts (mean: 4). The final efficacy was PR in 13, NC in 26 and PD in 1 for a response rate of 32.5 % (95% CI: 18.0–47.0%). The median survival time was 41.7 weeks (95% CI: 28.5–54.7 weeks). The median time to progressive disease was 19 weeks. Hematologic toxicities observed included Grade 3 or 4 neutropenia in 60%, Grade 3 or 4 anemia in 20%, and Grade 3 or 4 thrombocytepenia in 10%. Non-hematologic toxicities were mild except Grade 3 diarrhea in 3 pts and Grade 3 pneumonitis in 2 pts. There were no toxic deaths. Conclusions: The combination of weekly PTX and GEM is a feasible, well-tolerated, and active scheme for second-line treatment of advanced NSCLC. No significant financial relationships to disclose." @default.
• W2300929849 created "2016-06-24" @default.
• W2300929849 creator A5041846056 @default.
• W2300929849 creator A5054569233 @default.
• W2300929849 creator A5055518358 @default.
• W2300929849 creator A5068639431 @default.
• W2300929849 date "2006-06-20" @default.
• W2300929849 modified "2023-09-25" @default.
• W2300929849 title "Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer" @default.
• W2300929849 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.17096" @default.
• W2300929849 hasPublicationYear "2006" @default.
• W2300929849 type Work @default.
• W2300929849 sameAs 2300929849 @default.
• W2300929849 citedByCount "0" @default.
• W2300929849 crossrefType "journal-article" @default.
• W2300929849 hasAuthorship W2300929849A5041846056 @default.
• W2300929849 hasAuthorship W2300929849A5054569233 @default.
• W2300929849 hasAuthorship W2300929849A5055518358 @default.
• W2300929849 hasAuthorship W2300929849A5068639431 @default.
• W2300929849 hasConcept C126322002 @default.
• W2300929849 hasConcept C143998085 @default.
• W2300929849 hasConcept C197934379 @default.
• W2300929849 hasConcept C2776256026 @default.
• W2300929849 hasConcept C2776694085 @default.
• W2300929849 hasConcept C2777292972 @default.
• W2300929849 hasConcept C2778375690 @default.
• W2300929849 hasConcept C2779177807 @default.
• W2300929849 hasConcept C2780258809 @default.
• W2300929849 hasConcept C31760486 @default.
• W2300929849 hasConcept C71924100 @default.
• W2300929849 hasConcept C81729549 @default.
• W2300929849 hasConceptScore W2300929849C126322002 @default.
• W2300929849 hasConceptScore W2300929849C143998085 @default.
• W2300929849 hasConceptScore W2300929849C197934379 @default.
• W2300929849 hasConceptScore W2300929849C2776256026 @default.
• W2300929849 hasConceptScore W2300929849C2776694085 @default.
• W2300929849 hasConceptScore W2300929849C2777292972 @default.
• W2300929849 hasConceptScore W2300929849C2778375690 @default.
• W2300929849 hasConceptScore W2300929849C2779177807 @default.
• W2300929849 hasConceptScore W2300929849C2780258809 @default.
• W2300929849 hasConceptScore W2300929849C31760486 @default.
• W2300929849 hasConceptScore W2300929849C71924100 @default.
• W2300929849 hasConceptScore W2300929849C81729549 @default.
• W2300929849 hasLocation W23009298491 @default.
• W2300929849 hasOpenAccess W2300929849 @default.
• W2300929849 hasPrimaryLocation W23009298491 @default.
• W2300929849 hasRelatedWork W1533590436 @default.
• W2300929849 hasRelatedWork W2046160123 @default.
• W2300929849 hasRelatedWork W2052592373 @default.
• W2300929849 hasRelatedWork W2100029565 @default.
• W2300929849 hasRelatedWork W2101702686 @default.
• W2300929849 hasRelatedWork W2300929849 @default.
• W2300929849 hasRelatedWork W2378586341 @default.
• W2300929849 hasRelatedWork W2383259583 @default.
• W2300929849 hasRelatedWork W2589889914 @default.
• W2300929849 hasRelatedWork W2591183695 @default.
• W2300929849 isParatext "false" @default.
• W2300929849 isRetracted "false" @default.
• W2300929849 magId "2300929849" @default.
• W2300929849 workType "article" @default.